104
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients

, , , ORCID Icon, , ORCID Icon, , , ORCID Icon & show all
Pages 347-356 | Published online: 03 Feb 2021

References

  • Ujiie H, Yasufuku K. The importance of novel molecular biomarker of early stage lung adenocarcinoma. Transl Cancer Res. 2017;6:S964–S968. doi:10.21037/tcr.2017.06.12
  • Cadranel J, Ruppert AM, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev Oncol Hematol. 2013;88(3):477–493. doi:10.1016/j.critrevonc.2013.06.009
  • Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Manag Res. 2017;9:243–248. doi:10.2147/CMAR.S138643
  • Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiol. 2016;280(1):271–280. doi:10.1148/radiol.2016151455
  • Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. CT features of epidermal growth factor receptor–mutated adenocarcinoma of the lung: comparison with nonmutated adenocarcinoma. J Thorac Oncol. 2016;11(6):819–826. doi:10.1016/j.jtho.2016.02.010
  • Dai J, Shi J, Soodeen-Lalloo AK, et al. Air bronchogram: a potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules. Lung Cancer. 2016;98:22–28. doi:10.1016/j.lungcan.2016.05.009
  • Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. BMC Med Imaging. 2017;17(1):5. doi:10.1186/s12880-016-0175-3
  • Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K. [(1)(8)F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract. 2013;22(5):427–437. doi:10.1159/000346303
  • Wang H, Li J, Chen F, et al. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol. 2010;20(8):2013–2026. doi:10.1007/s00330-010-1743-5
  • Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009;4(2):e4576. doi:10.1371/journal.pone.0004576
  • Putora PM, Fruh M, Muller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology. 2013;18(4):734–735. doi:10.1111/resp.12083
  • Lee SM, Bae SK, Jung SJ, Kim CK. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Clin Nucl Med. 2015;40(12):950–958. doi:10.1097/RLU.0000000000000975
  • Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80. doi:10.1016/j.lungcan.2009.03.010
  • Guan J, Xiao NJ, Chen M, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine. 2016;95(30):e4421. doi:10.1097/MD.0000000000004421
  • Cho A, Hur J, Moon YW, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer. 2016;16:224. doi:10.1186/s12885-016-2251-z
  • Takamochi K, Mogushi K, Kawaji H, et al. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One. 2017;12(4):e0175622. doi:10.1371/journal.pone.0175622
  • Lv Z, Fan J, Xu J, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol I. 2018;45(5):735–750. doi:10.1007/s00259-017-3885-z
  • Gao X-C, Wei C-H, Zhang R-G, et al. 18 F-FDG PET/CT SUV max and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer. Oncol Lett. 2020;20(4):61. doi:10.3892/ol.2020.11922
  • Zhu L, Yin G, Chen W, et al. Correlation between EGFR mutation status and F18-fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. Thoracic Cancer. 2019;10(4):659–664. doi:10.1111/1759-7714.12981
  • Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010;27(1):9–15. doi:10.1007/s12032-008-9160-1
  • Ko KH, Hsu HH, Huang TW, et al. Value of (1)(8)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol I. 2014;41(10):1889–1897. doi:10.1007/s00259-014-2802-y
  • Kanmaz ZD, Aras G, Tuncay E, et al. Contribution of (1)(8)Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. Cancer Biomark. 2016;16(3):489–498. doi:10.3233/CBM-160588
  • Wang Q, Mou J, Yang X, et al. EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? Lung Cancer. 2013;4:27–33.
  • Chong GO, Lee YH, Hong DG, Cho YL, Lee YS. Unabsorbed polylactide adhesion barrier mimicking recurrence of gynecologic malignant diseases with increased 18F-FDG uptake on PET/CT. Arch Gynecol Obst. 2015;292(1):191–195. doi:10.1007/s00404-014-3587-8
  • Usuda K, Sagawa M, Motono N, et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev. 2014;15(2):657–662. doi:10.7314/APJCP.2014.15.2.657
  • Lee EYP, Khong P-L, Lee VHF, Qian W, Yu X, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med. 2015;40(3):e190–e195. doi:10.1097/RLU.0000000000000684
  • Yu C, Xia X, Qin C, Sun X, Zhang Y, Lan X. Is SUVmax helpful in the differential diagnosis of enlarged mediastinal lymph nodes? A pilot study. Contrast Media Mol I. 2018;2018:3417190. doi:10.1155/2018/3417190
  • Kim JH, Nam B, Choi YJ, et al. Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation. Cancer Res. 2018;78(16):4482. doi:10.1158/0008-5472.CAN-18-0117
  • Xu W, Yin G, Zhang Y. Predictive power of a radiomic signature based on 18F-FDG PET/CT images for EGFR mutational status in NSCLC. Front Oncol. 2019;9:1062. doi:10.3389/fonc.2019.01062
  • Yip SS, Kim J, Coroller TP, et al. Associations between somatic mutations and metabolic imaging phenotypes in non–small cell lung cancer. J Nucl Med. 2017;58(4):569. doi:10.2967/jnumed.116.181826